MX2021009285A - Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). - Google Patents

Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).

Info

Publication number
MX2021009285A
MX2021009285A MX2021009285A MX2021009285A MX2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A
Authority
MX
Mexico
Prior art keywords
novel
antibodies
binding
binding antibodies
human
Prior art date
Application number
MX2021009285A
Other languages
English (en)
Spanish (es)
Inventor
Gruijl Tanja Denise De
Der Vliet Johannes Jelle Van
Paul Parren
Weerdt Iris De
Aron Philip Kater
George Lodewijk Scheffer
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2021009285A publication Critical patent/MX2021009285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021009285A 2019-02-01 2020-01-30 Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). MX2021009285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Publications (1)

Publication Number Publication Date
MX2021009285A true MX2021009285A (es) 2021-11-12

Family

ID=71840475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009285A MX2021009285A (es) 2019-02-01 2020-01-30 Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).

Country Status (11)

Country Link
US (1) US20220135694A1 (https=)
EP (1) EP3917960A1 (https=)
JP (2) JP2022519082A (https=)
KR (1) KR20210141466A (https=)
CN (1) CN113993893A (https=)
AU (1) AU2020216250A1 (https=)
BR (1) BR112021015238A8 (https=)
CA (1) CA3128148A1 (https=)
MX (1) MX2021009285A (https=)
SG (1) SG11202108141VA (https=)
WO (1) WO2020159368A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
PL4269444T3 (pl) * 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
CA3200826A1 (en) * 2020-12-10 2022-06-16 Paul Willem Henri Ida PARREN Antibodies that bind gamma-delta t cell receptors
AU2022224391A1 (en) * 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
JP2024523316A (ja) 2021-06-18 2024-06-28 オートラス リミテッド Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用
AU2022332499A1 (en) * 2021-08-24 2024-03-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/cd40 binding molecule and medicinal use thereof
TW202328197A (zh) * 2021-09-24 2023-07-16 大陸商正大天晴藥業集團股份有限公司 抗cd40抗體及其用途
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
JP2025504363A (ja) * 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδＴ細胞結合ポリペプチド及びその使用
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
WO2024092150A2 (en) * 2022-10-26 2024-05-02 Providence Health & Services - Oregon Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
KR20260004605A (ko) * 2024-07-01 2026-01-09 주식회사 피비이뮨테라퓨틱스 길항성 항-cd40 인간화 항체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
DK3129404T3 (da) 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
WO2018011421A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Also Published As

Publication number Publication date
AU2020216250A1 (en) 2021-08-26
JP2025032324A (ja) 2025-03-11
CN113993893A (zh) 2022-01-28
CA3128148A1 (en) 2020-08-06
BR112021015238A2 (pt) 2022-02-15
KR20210141466A (ko) 2021-11-23
BR112021015238A8 (pt) 2022-08-16
EP3917960A1 (en) 2021-12-08
US20220135694A1 (en) 2022-05-05
WO2020159368A1 (en) 2020-08-06
SG11202108141VA (en) 2021-08-30
JP2022519082A (ja) 2022-03-18

Similar Documents

Publication Publication Date Title
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
CO2021005987A2 (es) Compuestos de anillo fusionado
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2019012756A (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats.
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
CO6660469A2 (es) Composiciones farmacéuticas de co- cristales de tramadol y coxibs
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
BR112018015603A2 (pt) ?conjugado de enzimas terapêuticas, seu método de preparação, composição farmacêutica, composição para aumentar a transcitose e seu método, composição para aumentar a distribuição de tecido de uma enzima e seu método?
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
BR112019024747A2 (pt) formulações de dose fixa
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
ECSP13012893A (es) Ureas asimétricas y usos médicos de las mismas
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2021004566A (es) Compuestos terapeuticos.